Clinical Trials Browser

Phase 1/2 × Matrix-M × 90 days × Clear all

NCT05683834 2026-04-22

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Phase 1/2 Completed

Herpes Simplex, Infectious Mononucleosis, Epstein-Barr Virus Infections